Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 5/20 | 0.37 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.37 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.37 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.37 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKCG | P05129 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | PRKCH | P24723 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.34 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.34 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19731772 | 0.82 | USP2 (0.53) | USP2TSHRHTTCYP3A4LPAR1 | |
| SCHEMBL128032 | 0.78 | — | — | |
| SCHEMBL13443053 | 0.77 | USP2 (0.39) | USP2TSHRHTTCYP3A4LPAR1 | |
| SCHEMBL7837995 | 0.77 | — | — | |
| SCHEMBL5957220 | 0.76 | USP2 (0.57) | USP2TSHRHTTCYP3A4LPAR1 | |
| SCHEMBL18029906 | 0.76 | USP2 (0.57) | USP2TSHRHTTCYP3A4LPAR1 | |
| SCHEMBL12854035 | 0.75 | — | — | |
| SCHEMBL7674482 | 0.74 | — | — | |
| SCHEMBL10339658 | 0.74 | USP2 (0.66) | USP2HTTLPAR1LPAR3LPAR2 | |
| SCHEMBL6937418 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362228-A1 | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESR1 | USP2 3054/4885TSHR 159/4885HTT 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.